This is the first week of cannabis earnings reports since Canada fully legalized all marijuana use on Oct. 17. The reports could be a bellwether for just how lucrative legalization will be for cannabis stocks in 2019.
Some of the biggest names in cannabis stocks reported earnings this week, including Aurora Cannabis Inc. (TSE: ACB), Tilray Inc. (NASDAQ: TLRY), Canopy Growth Corp. (NYSE: CGC), and Cronos Group Inc. (NASDAQ: CRON).
To help you ignore the noise and find the most profitable takeaways, we’ve put together a list of the three most important results for cannabis investors.
Just about every cannabis investor will find something to be excited about here too, from exploding revenue to the market creating even more opportunities to invest in.
And to help you make the most of these opportunities, we’ll also show you how to assemble the perfect cannabis stock portfolio…
Takeaway No. 3: Cannabis Revenue Is Surging
There was a lot of excitement about the growth potential marijuana legalization presented, and so far it has far exceeded the hype.
Cronos’s earnings report showed revenue surged 187%, even though it isn’t active in every Canadian province just yet. It’s also still waiting on a license to sell plants grown in its new 280,000-square-foot facility in Ontario.
Aurora announced its revenue rocketed 260% higher since this time last year. That’s due in part to Aurora comprising nearly a third of Ontario’s online marijuana sales since Oct. 17.
And Tilray nearly doubled its revenue since last year.
Perfect Pot Stock Portfolio: Every single stock is in the black. Learn more.
That revenue surge came even as marijuana prices fell more than a dollar per gram, dropping from $7.53 to $6.21 as the supply buildup before legalization weighed on prices. But the marijuana price drop is temporary. Growers will more effectively match their production to market demand now that it’s more predictable.
All told, revenue went through the roof for three of the biggest marijuana companies in the world thanks to Canada’s legalization, and that’s just the start. These companies are still expanding throughout Canada, are still waiting for complete recreational licenses, and marijuana prices will rebound soon. Those are three major catalysts moving forward.
Plus, we saw even more good news for marijuana in earnings reports…
Takeaway No. 2: Medicinal Marijuana Isn’t Taking a Hit – It’s Growing Too
Investors were concerned medical marijuana companies might lose market share to recreational use when all forms of cannabis were legalized.
That’s exactly the opposite of what happened.
Aurora actually saw in increase in medicinal customers since Canada legalized recreational cannabis. Tilray’s earnings report chalked up their 86% revenue surge to growing demand for medicinal marijuana.
Aurora’s CEO Terry Booth told analysts medical marijuana patient visits and demand grew after the Oct. 17 legalization date. He believes the biggest growth prospect in the industry remains in medicinal cannabis.
We’re encouraged too, since it means the growth prospects for both recreational and medicinal companies remain bright.
And it’s also why this remains one of the best opportunities to invest in cannabis stocks…
Takeaway No. 1: This Is Just the Start for Cannabis Stocks
While we saw some spectacular numbers in this week’s cannabis earnings reports, we also learned these companies are still figuring out how to navigate this new market.
And that’s presenting a tremendous opportunity for investors like you. It means there’s still time to get into this market, and some of the biggest gains are still on the way if you know which companies are poised to dominate the market.
Canopy stumbled out the gates, posting a small $2 million decline in revenue thanks to Canadian provinces only buying enough marijuana to “stress test” their systems. This limited buying certainly won’t last.
CEO Bruce Linton told analysts the company had to deal with some hiccups and bottlenecks, but they expect to turn in a banner year now that the initial hurdles are out of the way.
“Internally we talk about watching Usain Bolt race, where you’re seeing Bolt would always win but he didn’t start off leading because he had to get momentum going. We feel we’re in a bit more like that mode.”
Aurora, Cronos, and Tilray raked in huge revenue growth, but they also spent and incredible amount of money on marketing in the run-up to the Oct. 17 legalization date, which hurt their bottom lines.
Aurora spent about twice as much money on marketing as it did last year, forking over nearly $30 million, while Cronos wound up with a net loss of $5.5 million despite the revenue surge.
But these are the sorts of growing pains we expect for such a major shift in this industry, and it means there’s huge opportunity for investors who know where to look.
You could even buy a company like Canopy at a healthy discount right now. After all, it has the billion-dollar backing of a major beverage maker in Constellation Brands Inc. (NYSE: STZ), and traders are foolishly overreacting.
But not all pot stocks will hand you life-changing wins. In fact, often the companies making headlines are least likely to see the biggest gains.
These three stocks, on the other hand, are flying under the radar… for now. Each of them could see exponential stock price acceleration at any moment, and if you get in before that happens, you could turn a token stake into a lifetime of wealth.
We don’t know of any other sector providing anywhere near this level of growth now.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.